Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
AstraZeneca and Daiichi Sankyo's DATROWAY also demonstrated a highly statistically significant and clinically meaningful 43...
An objective response rate of 50.5% was observed with raludotatug deruxtecan across all dose levels in these patients in the ph...
Daiichi Sankyo and AstraZeneca's DATROWAY is the first and only therapy to significantly improve overall survival versus ch...
Second positive phase 3 trial of Daiichi Sankyo and AstraZeneca's ENHERTU in HER2 positive early breast cancer reinforces i...
Based on DESTINY-Breast09 phase 3 trial results, which showed ENHERTU plus pertuzumab reduced the risk of disease progression o...
Data from IDeate-Lung01 trial will be presented at upcoming IASLC 2025 World Conference on Lung CancerFirst Breakthrough Therap...
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...
TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca's DATROWAY with im...
